Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection
Autor: | Gayathri Krishna, Mohanan Valiya Veettil, Vinod Soman Pillai |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Coronavirus disease 2019 (COVID-19) Middle East respiratory syndrome coronavirus viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pneumonia Viral Therapeutics Biology medicine.disease_cause Antiviral Agents Virus Betacoronavirus 03 medical and health sciences 0302 clinical medicine Viral life cycle Full Length Article Drug Discovery Pandemic medicine Animals Humans Molecular Targeted Therapy Pandemics Pharmacology Antiviral targets SARS-CoV-2 Drug discovery COVID-19 virus diseases Outbreak Antivirals Virology 030104 developmental biology Coronavirus Infections 030217 neurology & neurosurgery |
Zdroj: | European Journal of Pharmacology |
ISSN: | 0014-2999 |
DOI: | 10.1016/j.ejphar.2020.173450 |
Popis: | Virus onslaughts continue to spread fear and cause rampage across the world every now and then. The twenty first century is yet again witnessing a gross global pandemic, Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Globally no vaccines or drug specific to COVID-19 is available. Corona viruses have been in mutual relationship with humans and other hosts over many decades though aggressive zoonotic strains have caused havoc. Zoonotic emergent corona viruses prior to SARS-COV-2 included severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the former leading to aggressive infectious spread and the later with high mortality rate. Although they emerged in the early period of the twenty first century, resilient biomedical and expertise in pharmaceutical domain could not appropriate any proprietary therapeutics. Studies envisaged towards curtailing their spread employed different stages of the virus life cycle with all zoonotic coronaviruses (CoVs) sharing genomic and structural similarities. Hence the strategies against SARS-CoV and MERS-CoV could prove effective against the recent outbreak of SAR-CoV-2. The review unravels key events involved in the lifecycle of SARS-CoV-2 while highlighting the possible avenues of therapy. The review also holds the scope in better understanding a broad-spectrum antivirals, monoclonal antibodies and small molecule inhibitors against viral glycoproteins, host cell receptor, viral mRNA synthesis, RNA-dependent RNA polymerase (RdRp) and viral proteases in order to design and develop antiviral drugs for SARS-CoV-2. Graphical abstract Image 1 Highlights • No specific anti-virals or vaccines have been developed for the control of SARS-CoV-2 infection till date. • Remdesivir, arbidol, lopinavir/ritonavir and a few more are repurposed for treating COVID-19. • Viral glycoprotein, host cell receptor, viral mRNA synthesis, RdRp and viral proteases are potential targets of SARS-CoV-2. • Anti-virals against SARS-CoV and MERS-CoV could also be repurposed to maximise therapeutic strategies against COVID-19. |
Databáze: | OpenAIRE |
Externí odkaz: |